Viral Vectors-Based Gene Therapy Market for Non-Human Primates to Surpass US$ 92.76 Million by 2034
Author : kaustubh Ravan | Published On : 25 Jun 2026
The global viral vectors-based gene therapy for non-human primates market was valued at US$ 29.97 million in 2023. The market is anticipated to expand at a CAGR of 11.0% from 2024 to 2034 and is expected to reach more than US$ 92.76 million by 2034. Increasing demand for translational research models, growing prevalence of genetic disorders, and expanding pipelines of gene and cell therapies are driving market growth globally. Viral vectors such as adeno-associated viruses (AAV), lentiviruses, and adenoviruses are widely used in NHP studies to evaluate safety, efficacy, and immune response before clinical trials in humans.
Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86394
The growing emphasis on precision medicine and advanced therapeutic development is significantly boosting demand for NHP-based gene therapy research. Pharmaceutical and biotechnology companies are increasingly relying on non-human primate models to bridge the gap between rodent studies and human clinical trials. Additionally, rising investments in rare disease research and regenerative medicine are expected to support market expansion throughout the forecast period.
Technological advancements in viral vector engineering, gene delivery systems, CRISPR-based editing integration, and improved vector safety profiles are transforming the market landscape. Companies and research institutions are focusing on enhancing transduction efficiency, reducing immunogenicity, and improving long-term gene expression stability in NHP models. Furthermore, increasing collaboration between academic institutes, CROs, and biopharmaceutical companies is expected to create new growth opportunities during the forecast period.
Key Findings of the Market Report
● Increasing adoption of NHP models in gene therapy research is expected to drive market growth.
● AAV vectors continue to dominate due to high efficiency and safety profile.
● Neurological and rare disease research applications are witnessing strong demand.
● Advancements in viral vector engineering are accelerating innovation in preclinical studies.
● Growing investments in gene therapy pipelines are creating significant growth opportunities.
Global Viral Vectors-based Gene Therapy for Non-human Primates Market: Growth Drivers
· Rising demand for translational research models bridging preclinical and clinical studies is significantly boosting market growth.
· Increasing prevalence of genetic and rare diseases is supporting demand for advanced gene therapy development.
· Expanding biopharmaceutical R&D investments are accelerating market expansion.
· Technological advancements in viral vector design and gene delivery systems are improving therapeutic outcomes.
· Growing collaborations between research institutes, CROs, and biotech companies are expected to support long-term market growth.
Global Viral Vectors-based Gene Therapy for Non-human Primates Market: Regional Landscape
· North America is expected to witness strong market growth owing to advanced biomedical research infrastructure and high gene therapy R&D investments.
· Europe is anticipated to experience steady growth due to strong academic research networks and supportive regulatory frameworks.
· Asia Pacific is projected to emerge as a growing market driven by expanding biotech research capabilities and increasing investment in advanced therapeutics.
Global Viral Vectors-based Gene Therapy for Non-human Primates Market: Key Players
Major market participants are focusing on viral vector innovation, gene therapy development platforms, strategic collaborations, and expansion of preclinical research capabilities to strengthen their market position.
● Regenxbio Inc.
● Sarepta Therapeutics, Inc.
● Novartis AG
● Bluebird Bio, Inc.
● F. Hoffmann-La Roche AG
● UniQure N.V.
● Thermo Fisher Scientific Inc.
● Charles River Laboratories
● Lonza Group AG
● WuXi AppTec
Key Developments
● Companies are increasingly investing in next-generation viral vector engineering to improve safety, targeting efficiency, and gene expression durability in NHP models.
● Growing demand for preclinical gene therapy validation is accelerating innovation and collaboration across biotech, pharma, and research organizations.
Global Viral Vectors-based Gene Therapy for Non-human Primates Market: Segmentation
By Vector Type
● Adeno-Associated Virus (AAV)
● Lentivirus
● Adenovirus
● Other Viral Vectors
By Application
● Neurological Disorders
● Rare Genetic Diseases
● Oncology Research
● Cardiovascular Research
● Infectious Disease Research
By End-user
● Pharmaceutical & Biotechnology Companies
● Academic & Research Institutes
● Contract Research Organizations (CROs)
By Research Phase
● Preclinical Studies
● Translational Research
● Toxicology Studies
By Region
● North America
● Europe
● Asia Pacific
● Latin America
● Middle East & Africa
Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=86394<ype=S
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: [email protected]
